Jump to content

Trenbolone hexahydrobenzylcarbonate

From Wikipedia, the free encyclopedia
Trenbolone hexahydrobenzylcarbonate
Clinical data
Trade namesParabolan, Hexabolan
Other namesTrenbolone cyclohexylmethylcarbonate; Estra-4,9,11-trien-17β-ol-3-one 17β-cyclohexylmethylcarbonate
Routes of
administration
Intramuscular injection
Drug classAndrogen; Anabolic steroid; Androgen ester; Progestogen
Identifiers
  • Cyclohexylmethyl [(8S,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,14,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl] carbonate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.041.503 Edit this at Wikidata
Chemical and physical data
FormulaC26H34O4
Molar mass410.554 g·mol−1
3D model (JSmol)
  • C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)OCC5CCCCC5
  • InChI=1S/C26H34O4/c1-26-14-13-21-20-10-8-19(27)15-18(20)7-9-22(21)23(26)11-12-24(26)30-25(28)29-16-17-5-3-2-4-6-17/h13-15,17,22-24H,2-12,16H2,1H3/t22-,23+,24+,26+/m1/s1
  • Key:GQJSFWYQKNQCIK-APFRJGHOSA-N

Trenbolone hexahydrobenzylcarbonate, or trenbolone cyclohexylmethylcarbonate, sold under the brand names Parabolan and Hexabolan, is a synthetic, injected anabolic–androgenic steroid (AAS) of the nandrolone group and an androgen ester – specifically, the C17β hexahydrobenzylcarbonate (cyclohexylmethylcarbonate) ester of trenbolone – which was marketed in France for medical use in humans but has since been discontinued.[1]

It was introduced in France in 1980 and was voluntarily discontinued by its manufacturer in 1997.[1][2] The drug acts as a long-lasting prodrug of trenbolone when administered via intramuscular injection.[1] It was used clinically at a dosage of one ampoule (76 mg, corresponding to 50 mg trenbolone base) every 10 days.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. pp. 619–. ISBN 978-0-9828280-1-4.
  2. ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 3307–. ISBN 978-0-8155-1856-3.

Further reading

[edit]
  • Yarrow JF, McCoy SC, Borst SE (2010). "Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity". Steroids. 75 (6): 377–89. doi:10.1016/j.steroids.2010.01.019. PMID 20138077. S2CID 205253265.
[edit]